Massive Bio Reaffirms Global Growth Strategy with Key C-Suite Hires and Executive Director Appointments – Yahoo Finance

Fueled by increased demand from pharmaceutical companies and a $16.5 million new funding in 2022 to accelerate innovative cancer trial enrollment and oncology solutions using artificial intelligence
NEW YORK, December 15, 2022–(BUSINESS WIRE)–Massive Bio, a leader in AI-powered cancer clinical trial enrollment, today announced the addition of two executives to its C-suite. Verily veteran Özgür "Oz" Huner joins as Massive Bio’s first Chief Product Officer, and Erkan Terzi has been promoted to Chief Marketing Officer. Both executives will report to CEO and co-founder Selin Kurnaz and work alongside co-founders Chief Medical Officer Arturo Loaiza-Bonilla and Chief Technology Officer and Chief Operating Officer Cagatay Culcuoglu in leading and driving Massive Bio’s product and growth strategy.
Huner and Terzi bring robust leadership experiences and strong legacies of success to the company. Oz brings more than 20 years of experience leading development of clinical and genomics products for cancer research and treatment. His prior roles include Molecular Products Lead at Verily Life Sciences, Alphabet Inc.’s research organization devoted to the study of life sciences, and extensive prior leadership experiences in oncology and genomics solutions at Sema4, QIAGEN, Genomic Health, Lifelabs, NexJ and Deloitte. Oz will lead the development of scalable product management processes to support Massive Bio’s accelerated growth and catalyze development of novel software and data products to enable new opportunities in the clinical trials value chain.
Terzi oversees creative and brand marketing, advertising, public relations, product management, digital marketing, and business intelligence. Erkan has extensive experience in developing and managing innovative marketing programs for many leading brands, including Allianz, Comcast Spotlight, LG Electronics, and Aselsan and has led Massive Bio through a successful growth period. Terzi has also authored several marketing books.
"Our mission is to create hope and empower cancer patients by helping them find the best treatment options, which often requires urgent access to trials," said Selin Kurnaz, co-founder and CEO of Massive Bio. "This is a monumental point in time where advanced technology is intersecting with medical science to meaningfully change lives. The addition of these highly seasoned experts will be instrumental in pushing the envelope in our mission as we move into 2023 and continue to execute on our strategic priorities."
The new hires are an outcome of Massive Bio’s latest $16.5 million funding round, which brought the company’s total raise to $23.3 million from its inception. The latest round of investors were Revo Capital, Kenan Turnacioglu, IFC (World Bank), DEG-Deutsche Investitions-und Entwicklungsgesellschaft mbH, TFS Services, ImpactAssets, and SiteGround Capital. The global nature of their investors helps Massive Bio to capture the global oncology clinical trial enrollment market and further accelerates its multi-country expansion plans.
In addition to the C-suite additions, Massive Bio hired Gretchen O’Neill as Executive Director of Clinical Operations, overseeing program management, client relations, and strategic partnerships. A PPD veteran, O’Neill has extensive experience in patient recruitment and retention, supporting top pharmaceutical and biotech companies, leading a best-in-class project management organization, governance-level client management, and oversight of study service delivery.
"Massive Bio’s strategy and commitment to individuals diagnosed with cancer sets us apart," O’Neill said. "The care factor for the people we help is unrivaled and it comes from the top down."
The company also announced the addition of David Henka as Director of Global Strategic Partnerships. Henka will be tasked with expanding Massive Bio’s relationships with payors, self-insured employers, health systems, research networks and other collaborators to provide access to cancer clinical trials from anywhere in the world. Henka served as the Senior Director of Partnerships and Business Development at Memorial Sloan Kettering Cancer Center, leading cancer screening, awareness, prevention, and High-Risk Surveillance Management (HRSM) for employers and plan sponsors. Henka brings decades of experience consulting with employers and health plan sponsors on a wide range of employee benefit issues, including plan design, benefit strategies, funding, and plan management.
"Oz, Erkan, Gretchen, and David bring proven track records of expertise in building strong product, growth, business and technology teams for market-leading companies in the oncology and clinical research industry, and will enable Massive Bio to continue its hypergrowth towards becoming the leading global AI-powered company in cancer clinical trials," said Dr. Arturo Loaiza-Bonilla.
Massive Bio recently announced onboarding more than 100,000 patients onto its trial matching platform. Its platform provides cancer patients with relevant clinical trials using AI, empowering patients to find treatment options faster and enabling life sciences companies to conduct broader, more-inclusive, population-based recruitment rather than traditional site-specific recruitment. Massive Bio’s AI technology can improve healthcare access and equity by automatically matching patient data to cancer trial data to enhance the patient experience in ways they could not do before.
About Massive Bio:
Massive Bio empowers cancer patients to find their best treatment options, providing convenient access and enrollment services for oncology clinical trials worldwide, powered by advanced artificial intelligence. Founded on the belief that all people should have equal access to leading-edge therapies, Massive Bio combines its best-in-class AI platform with expertise in genomics, engineering, and data analytics to remove the many barriers to cancer patient enrollment and participation in clinical trials. Headquartered in New York, Massive Bio is a privately held company that operates in 12 countries.
View source version on
Massive Bio: Lisa Barbadora,, +1 610-420-3413
Standard Chartered PLC (SCBFF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
The legendary investor has just posted a message that might discourage investors from buying stocks.
“We just launched a rocket and got it to the moon,” said co-chief executive Helmy Eltoukhy. “It's illogical, irrational, and people don't understand the science.”
Guardant unveiled results for its colon cancer-detecting blood test Thursday that lagged rival Exact. GH stock crashed as EXAS stock jumped.
(Bloomberg) — Guardant Health Inc. fell more than 45% in late trading Thursday after results of a study of its blood test for colorectal cancer disappointed investors. Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkUS Stocks Drop for a Second Day; Oil Snaps Rally: Markets WrapThe test accurately identified the presence of cancer or prec
Investor concerns have yet to abate, with worries given some added impetus this week when Fed Chair Jerome Powell said that the central bank is expecting interest rates to rise to 5.1% by the end of 2023. At that rate, many economists fear that a recession is inevitable. In fact, as a sign that recession might be on the horizon, November retail-sales data showed the biggest drop in over a year. The immediate result was a sudden drop in stocks across the board, but the unintended consequence may
In early trading, shares of Western Digital (NASDAQ: WDC), a manufacturer of computer hard disk drives and solid state drives, plunged more than 10%. Worse, the damage seems to be spreading throughout the computer hardware industry, with shares of semiconductors specialist Intel (NASDAQ: INTC) tumbling 3.3%, and Qualcomm (NASDAQ: QCOM) following everyone else lower — down 3.8%. This morning, Goldman Sachs (NYSE: GS) downgraded Western Digital stock from neutral to sell and cut its price target 28% to just $31 a share.
“Investor frustration is building as the Musk brand has quickly deteriorated over the past six months,” the influential tech analyst wrote. “The Twitter nightmare continues.”
(Bloomberg) — Bulls reeling from the Federal Reserve’s still-hawkish tilt are about to lose a major force that helped tamp down turbulence in US stocks during this week’s macroeconomic drama.Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkUS Stocks Drop for a Second Day; Oil Snaps Rally: Markets WrapAn estimated $4 trillion of options is
Most investors at least have a few stocks they can brag about. Not so this year with Cathie Wood's ARK Innovation.
Stocks have been on a wild ride this week, and conditions could still get weirder as traders brace for "quadruple witching" on Friday, when a flurry of equity options and futures contracts expire.
Yahoo Finance Live anchor Seana Smith checks out several stocks trending in the after-hours trading session.
Tesla investors are starting to wonder if CEO Elon Musk is still the right man to lead the company after he acquired Twitter.
More than 100 years of history shows that the U.S. stock market tends to avoid booking back-to-back annual losses, according to AGF Investments.
With inflation rates this year reaching levels not seen since the early 1980s, and the Fed taking aggressive interests rate hikes in its attempt to tame it, these issues have been hot topics in 2022. This is a conversation unlikely to go away anytime soon, however, according to legendary investor Howard Marks. “Inflation and interest rates are highly likely to remain the dominant considerations influencing the investment environment for the next several years,” the billionaire said in a recent n
FTSE muted as traders digest weak retail sales figures and take stock after the Bank of England raised interest rates.
(Bloomberg) — Commodities will be the best-performing asset class once again in 2023, handing investors returns of more than 40%, according to Goldman Sachs Group Inc.Most Read from BloombergIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkPowell Says Fed Still Has a ‘Ways to Go’ After Half-Point HikeStocks Push Lower as Traders Digest Rate Moves: Markets WrapThe Wall Street bank said that while the first quarter may be “bumpy”
(Bloomberg) — U.S. equity-index futures dropped with European stocks amid concern the resolve of central banks to continue their fight against inflation will tip the economy into a recession.Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesIs Putin Finally Getting Smart About His Ukraine Disaster?Elon Musk’s Tesla Share Sales Approach the $40 Billion MarkUS Stocks Drop for a Second Day; Oil Snaps Rally: Markets WrapContracts on the S&P 500 and Nasdaq 10
The Nasdaq undercut key support on recession fears, with Apple tumbling. Little is working, but here's the silver lining,
The collapse of FTX has sparked a crisis of confidence as crypto tries to rebuild its tarnished reputation. What's ahead for 2023.


Leave a Comment